All questionsPharmacology: Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer4 questions · 2 sourcesMechanismHow does DATROWAY work (mechanism of action)?“Datopotamab deruxtecan-dlnk, is a Trop-2-directed antibody-drug conjugate. The antibody is a humanized anti-Trop2 IgG1. The small molecule, DXd, is a topoisomerase I inhibitor attached to the antibody by a cleavable linker. Following binding to Trop-2 on cells, including tumor cells, datopotamab deruxtecan-dlnk undergoes internalization and intracellular linker cleavage by lysosomal enzymes. Upon release, the membrane-permeable DXd causes DNA damage and apoptotic cell death.” (opens the source at this quote in a new tab)CopyFlag“DATROWAY is a specifically engineered Trop-2-directed antibody-drug conjugate1,2 Designed to induce selective tumor cell death and reduce systemic exposureto the topoisomerase I inhibitor payload Trop-2-directed mAb1,2* Leverages Trop-2, a cell surface protein, to provide selective delivery of cytotoxic agent Tumor-selective cleavable linker1-3*† Attaches payload to the antibody Linker-payload is stable in plasma Linker is selectively cleaved by enzymes that are upregulated in tumor cells DXd payload1-4*† Potent topoisomerase I inhibitor payload with a short systemic half-life Upon release, membrane-permeable payload causes DNA damage and cell death, resulting in destruction of targeted tumor cells and neighboring cells present in the tumor microenvironment, known as the bystander antitumor effect * Information from laboratory studies suggests that this is how DATROWAY works.2 † Based on animal data. The clinical relevance of these features is under investigation.2” (opens the source at this quote in a new tab)CopyFlagPharmacokineticsHow is DATROWAY metabolized?“Datopotamab deruxtecan-dlnk undergoes intracellular cleavage by lysosomal enzymes to release DXd. The humanized Trop-2 IgG1 monoclonal antibody is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG. In vitro, DXd is primarily metabolized by CYP3A4.” (opens the source at this quote in a new tab)CopyFlagWhat is the half-life of DATROWAY?“The datopotamab deruxtecan-dlnk median elimination half-life (t1/2) is 4.8 days (1.0, 8.2) and the released DXd median apparent t1/2 is approximately 5.5 days (3.2, 8.8). The estimated datopotamab deruxtecan-dlnk clearance is 0.6 (31.5%) L/day.” (opens the source at this quote in a new tab)CopyFlagComponentsWhat are the ingredients in DATROWAY?“DATROWAY (datopotamab deruxtecan-dlnk) for injection is a sterile, white to yellowish white, preservative-free lyophilized powder in single-dose vials. Each vial delivers 100 mg of datopotamab deruxtecan-dlnk, L-histidine (3.88 mg), L-histidine hydrochloride monohydrate (5.25 mg), polysorbate 80 (1.50 mg), and sucrose (450 mg).” (opens the source at this quote in a new tab)CopyFlag